|

Medication Errors in Hospitalized Cardiovascular
Patients
Nancy M. Allen LaPointe, PharmD; James G. Jollis,
MD
Arch Intern Med. 2003;163:1461-1466.
Background The Institute of Medicine's report To
Err Is Human: Building a Safer Health System
recommends pharmacist participation in patient rounds as
an immediate approach to reducing medical errors. In the
same report and in prior publications, cardiovascular
drugs have been commonly associated with severe adverse
drug events.
Methods We systematically reviewed the experience of a
clinical pharmacist on the cardiology wards between September
1, 1995, and February 18, 2000. We classified medication
errors according to the type of error, medications
involved, personnel involved, stages of drug
administration involved, and time of year most frequently
associated with errors.
Results Among 14 983 pharmacist interventions, 4768
were related to medication errors, or 24 medication errors per
100 admissions. The most common errors involved the wrong drug
(36.0%) or wrong dose (35.3%), and cardiovascular medications
were involved in 41.2% of the errors. Prescribers were
associated with most of the errors, and the transition
from outpatient to inpatient was the most common point in
the system for the occurrence of these medication errors.
Higher numbers of errors were also identified during the
transition period of house staff, and the total number of
errors increased during the study period.
Conclusions Through the clinical pharmacist's
identification and correction of medication errors, 2
areas of improvement that may reduce medication errors
were identified. The first is ensuring accurate knowledge
of a patient's outpatient medication regimen. The second
involves improving the education and support of new
interns during their initial months of training. This
work exemplifies the approach recommended by the Institute of
Medicine to reduce medical errors through systematic analyses
rather than ascribing fault to individuals.
From the
Duke Center for Education and Research on Therapeutics, Duke
Clinical Research Institute, and the Division of Cardiology, Duke
University Medical Center, Durham, NC. The authors have no relevant
financial interest in this article.
RELATED ARTICLES IN ARCHIVES OF
INTERNAL MEDICINE
In This Issue of Archives of Internal Medicine
Arch Intern Med. 2003;163:1389.
FULL TEXT
|